Accumed Research Associates

1. IBSA Institut Biochimique SA $736,145 13 payments
2. Upsher-Smith Laboratories LLC $613,476 10 payments
3. AbbVie, Inc. $562,014 78 payments
4. Endo Pharmaceuticals Inc. $409,401 42 payments
5. Allergan Inc. $333,607 49 payments
6. Urovant Sciences Inc $201,512 56 payments
7. Tolmar, Inc. $169,062 24 payments
8. Sumitomo Pharma America, Inc. $152,138 18 payments
9. Urogen Pharma, Inc. $118,222 90 payments
10. OPKO Pharmaceuticals, LLC $86,984 7 payments

1. A multi-center, prospective, randomized, double-blind, flexible-dose, placebo-controlled, parallel group clinical trial of Sildenafil oral film 25 mg, 50 mg, 75 mg and 100 mg for the treatment of erectile dysfunction (ED) $736,145 13 payments
2. Vogelxo(R) Abpm Study in Hypogandal Men $613,476 10 payments
3. An Open-Label, Randomized, Parallel-Group, Three Treatment Arm, Multicenter Study on Hypogonadal Males to Evaluate the Effect on 24-Hour Ambulatory Blood Pressure After 16-Week Continuous Treatment with Marketed Testosterone Products $409,401 42 payments
4. M16-100 $268,101 31 payments
5. A Phase 3 Double-Blind, Randomized, Placebo-Controlled, Multi-Center Study to Evaluate the Efficacy, Safety and Tolerability of Vibegron in Men With Overactive Bladder (OAB) Symptoms on Pharmacological Therapy for Benign Prostatic Hyperplasia (BPH) $237,491 21 payments
6. M19-161 $141,522 9 payments
7. Tol-Clar-20024 $127,054 18 payments
8. Androderm 24-Hr ABPM $119,481 8 payments
9. A Study Evaluating the Efficacy and Safety of BOTOX Intravesical Instillation in Patients with Overactive Bladder and Urinary Incontinence $112,044 14 payments
10. Effects and Safety of OPK-88004 Doses in Men With Signs and Symptoms of Benign Prostatic Hyperplasia (BPH) $86,984 7 payments

1. Patient care $5,060 2 payments

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.